NCT01881633已完成1 期
A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Safety and tolerability
研究概览
简要总结
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of single dosing study with three ascending dose cohorts of ISU302 in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male volunteers, aged between ≥ 20 and ≤ 45 years old
- •Weight ≥ 50, with calculated body mass index of 17 and 25 kg/m2
- •BMI = (Weight [kg])/(height [m])2
- •Subject is informed of the investigational nature of this study and voluntarily agrees to participate in this study and comply with the relevant instructions in written
- •Considered ineligible through screening test (such as medical history, physical examination, ECG, safety laboratory test) performed within 35 days prior to study start (dosing of investigational products)
排除标准
- •With symptoms indicating acute diseases within 28 days prior to start of study (dosing of investigational product)
- •History or presence of clinically significant and active cardiovascular, respiratory, renal, endocrine, hematological, gastrointestinal, central nervous system, psychiatric disorder, autoimmune disease, or malignant tumor
- •Any medical history that may affect drug absorption, distribution, metabolism and excretion(e.g., inflammatory gastric disease, gastric or intestinal ulcer, hepatic or renal disease)
- •With presence of clinically significant allergic disease (including mild allergic rhinitis or allergic dermatitis which does not need medication)
- •With presence of clinically significant hypersensitivity to any drugs
- •With hemolytic anemia, anemia due to blood loss (Hb < 14g/dL and Hct <42%)
- •With the results of safety laboratory test
- •AST (Aspartate Transaminase) or ALT (Alanine Transaminase) > 1.5 times of upper normal limit
- •Total bilirubin > 1.5 times of upper normal limit
- •Subject who has immune deficiency or medication with immune suppressants
- •Participation in other clinical study within 60 days prior to start of study (dosing of investigational products)
- •Use of any drugs, possibly affecting drug metabolizing enzymes, within 1 month prior dosing, or any drugs, possibly affecting the results of clinical trial within 10 days or use of drug was not passes 5 x half-life of drug
- •Donated whole blood within 60 days, or transfused within 20 days before the study
- •History of alcohol abuse (> 14 units/week) and the subject could not stop drinking alcohol beverage during study period
- •Heavy smoker (>10 cigarettes/day) or the subject could not stop smoking during study period
- •Unwillingness or inability to follow the procedures outlined in the protocol
- •Positive in pregnancy test in urine and unwilling to follow contraception during study period and following 3 months (for female subjects).
研究组 & 干预措施
ISU302 30 U/kg
Experimental
Drug ISU302 I.V. injection
干预措施: ISU302 (Drug)
ISU302 60 U/kg
Experimental
Drug ISU302 I.V. injection
干预措施: ISU302 (Drug)
Placebo
Placebo Comparator
ISU302 Placebo I.V. injection
干预措施: Placebo (Drug)
ISU302
Experimental
15 U/kg I.V. injection
干预措施: ISU302 (Drug)
结局指标
主要结局
Safety and tolerability
时间窗: From Screening to Day 5 post-dose
Evaluation for safety data by treatment group/ Confirmative evaluation for serious adverse drug reaction/ Descriptive statistics (arithmetic mean and standard deviation) for quantitative analysis and evaluation of change from baseline/ Frequency counts for qualitative categorization of safety data Parameters: * Adverse events including subjective/objective symptoms * Physical examination * 12-lead ECG * Vital signs * Local tolerability test * Clinical laboratory test: Hematology, Coagulation, Blood Chemistry, Urinalysis * Immunogenicity
次要结局
- Pharmacokinetics(Day1)
研究者
相似试验
已完成
1 期
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian ParticipantsHealthy VolunteersNCT05806359Bristol-Myers Squibb33
已完成
1 期
Single Dose of PF-06835919 Escalation Study in Healthy Adult SubjectsNon-alcoholic Fatty Liver DiseaseNCT02974374Pfizer16
已完成
1 期
SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy SubjectsHealthyNCT02657122Theravance Biopharma72
已完成
1 期
Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy VolunteersHealthyNCT02572349Cyclerion Therapeutics24
已完成
1 期
A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on MethotrexatePharmacokinetics of ASP2409Rheumatoid ArthritisNCT02171143Astellas Pharma Global Development, Inc.58